In addition, targetable mutations as well as fusion genes need to be analyzed as they provide therapeutic options for pediatric cancer (19), such as BRAF fusions/mutation in low-grade gliomas and NTRK fusions in several tissue types showing promising results in pediatric clinical trials (20). The gene discussed is BRAF; the disease is glioma.